{{Rsnum
|rsid=2914295
|Gene=ADCY2
|Chromosome=5
|position=7652721
|Orientation=plus
|GMAF=0.3866
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=ADCY2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 14.2 | 39.8 | 46.0
| HCB | 17.5 | 49.6 | 32.8
| JPT | 15.0 | 47.8 | 37.2
| YRI | 16.3 | 48.3 | 35.4
| ASW | 8.8 | 50.9 | 40.4
| CHB | 17.5 | 49.6 | 32.8
| CHD | 15.6 | 45.0 | 39.4
| GIH | 31.7 | 52.5 | 15.8
| LWK | 7.3 | 50.9 | 41.8
| MEX | 24.1 | 48.3 | 27.6
| MKK | 16.7 | 55.1 | 28.2
| TSI | 14.7 | 45.1 | 40.2
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2914295
|Name_s=
|Gene_s=ADCY2
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 176. Study population/ethnicity: 87 European descent Caucasians and 89 Yorubans. Significance metric(s): p = 0.00008. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109318
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2914295
|overall_frequency_n=80
|overall_frequency_d=128
|overall_frequency=0.625
|n_genomes=51
|n_genomes_annotated=0
|n_haplomes=71
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}